<?xml version='1.0' encoding='utf-8'?>
<document id="31836927"><sentence text="Impact of the organic cation transporter 2 inhibitor cimetidine on the single-dose pharmacokinetics of the glucosylceramide synthase inhibitor lucerastat in healthy subjects."><entity charOffset="53-63" id="DDI-PubMed.31836927.s1.e0" text="cimetidine" /><entity charOffset="107-123" id="DDI-PubMed.31836927.s1.e1" text="glucosylceramide" /><pair ddi="false" e1="DDI-PubMed.31836927.s1.e0" e2="DDI-PubMed.31836927.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31836927.s1.e0" e2="DDI-PubMed.31836927.s1.e1" /></sentence><sentence text="Lucerastat is an orally available glucosylceramide synthase inhibitor with a potential to provide substrate reduction therapy for Fabry patients independent of their α-galactosidase A genotype"><entity charOffset="34-50" id="DDI-PubMed.31836927.s2.e0" text="glucosylceramide" /></sentence><sentence text=" In humans, lucerastat is mainly eliminated as unchanged parent compound through renal excretion both by active secretion and passive filtration" /><sentence text=" In vitro studies indicated that lucerastat is a substrate of human organic cation transporter 2 (OCT2) mainly expressed in the kidney" /><sentence text="" /><sentence text="Therefore, this clinical study, conducted in 14 healthy male subjects, investigated the effect of 800 mg twice-daily oral administration of the OCT2 inhibitor cimetidine at steady state on the single-dose pharmacokinetics (PK) of 500 mg lucerastat"><entity charOffset="159-169" id="DDI-PubMed.31836927.s6.e0" text="cimetidine" /></sentence><sentence text=" The safety and tolerability of lucerastat administered alone and concomitantly with cimetidine were also evaluated"><entity charOffset="85-95" id="DDI-PubMed.31836927.s7.e0" text="cimetidine" /></sentence><sentence text="" /><sentence text="Exposure to lucerastat was slightly higher upon co-administration of cimetidine indicated by geometric mean area under the plasma concentration-time curve from zero to infinity (AUC0-∞) ratio of 1"><entity charOffset="69-79" id="DDI-PubMed.31836927.s9.e0" text="cimetidine" /></sentence><sentence text="22 (90% confidence interval [CI] 1" /><sentence text="16-1" /><sentence text="28)" /><sentence text=" Cimetidine delayed the time to reach maximum lucerastat concentrations (tmax) by 1 h but did not affect its elimination half-life (t½) or maximum plasma concentration (Cmax) as geometric mean ratios were 1"><entity charOffset="1-11" id="DDI-PubMed.31836927.s13.e0" text="Cimetidine" /></sentence><sentence text="00 (0" /><sentence text="91-1" /><sentence text="10) and 1" /><sentence text="04 (0" /><sentence text="92-1" /><sentence text="17), respectively, at cimetidine steady state"><entity charOffset="22-32" id="DDI-PubMed.31836927.s19.e0" text="cimetidine" /></sentence><sentence text=" Lucerastat was safe and well tolerated when given alone and in combination with cimetidine"><entity charOffset="81-91" id="DDI-PubMed.31836927.s20.e0" text="cimetidine" /></sentence><sentence text="" /><sentence text="These results indicate that the single-dose PK of lucerastat are not changed to a clinically relevant extent by cimetidine-mediated OCT2 inhibition, allowing the concomitant use of OCT2 inhibitors with lucerastat without any need for dose adjustment"><entity charOffset="112-122" id="DDI-PubMed.31836927.s22.e0" text="cimetidine" /></sentence><sentence text="" /><sentence text="EudraCT: 2017-003725-14; ClinicalTrials" /><sentence text="gov: NCT03380455" /><sentence text="" /></document>